SchooLinks Recognized Among America's Best Startup Employers by Forbes and Inc.
May 08, 2024 07:15 ET
|
SchooLinks
Austin, TX, May 08, 2024 (GLOBE NEWSWIRE) -- SchooLinks, the most innovative platform for college and career readiness, is proud to announce its recent achievements in both business growth and...
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024 07:05 ET
|
uniQure Inc.
uniQure announces first quarter 2024 results
Inc.’s 2024 Female Founders list highlights why female founders are always a good bet
April 09, 2024 12:19 ET
|
Adyn, Inc.
Inc’s 2024 Female Founders list highlights why female founders are always a good bet. adyn founder, Elizabeth Ruzzo, is named to the list.
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024 07:05 ET
|
uniQure Inc.
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory...
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023 07:05 ET
|
uniQure Inc.
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
Comprise named top agency in several business, PR and marketing awards programs
December 19, 2023 06:00 ET
|
Comprise
Boulder, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Comprise® solidified its status as a leading communications agency delivering integrated public relations and digital marketing services with the...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 29, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 07, 2023 07:05 ET
|
uniQure Inc.
~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase...
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...